Aclaris 制药 ACRS
$3.90 +$0.29 (+8.03%)
休市 · Nov 6, 10:00 pm ET · 最新盘后价 $3.90 0.00%
开盘$3.62
昨收$3.61
当日区间$3.61 – $3.98
成交量3.53M
市值$618.59M
市盈率（TTM）–
股息率–
基本面
最新报告季度：Q2, ended Jun 2026
营收$1.63M-8.3% YoY
营业利润-$23.94M-41.6% YoY
净利润-$21.51M-39.4% YoY
摊薄每股收益-$0.15-15.4% YoY
自由现金流-$19.91M-116.8% YoY
经营现金流-$19.85M
营收，近8个季度
净利润，近8个季度
各季度摊薄每股收益
各季度自由现金流
年度营收
盈利能力与资产负债表
毛利率12.9%
营业利润率-1,040.4%
净利率-921.5%
净资产收益率-59.1%
资产收益率-41.1%
投入资本回报率-64.3%
流动比率3.46
负债/资产比率30.7%
现金及投资$91.56M
净现金（净负债）$91.56M
利润表
| 项目 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| 报告营业总收入 | $1.63M | $2.00M | $7.83M | $1.30M | $3.30M |
| 营业总收入 | $1.63M | $2.00M | $7.83M | $1.30M | $3.30M |
| 营业成本 | $1.45M | $1.79M | $7.28M | $1.47M | $2.45M |
| 毛利润 | $176,000.00 | $208,000.00 | $542,000.00 | -$174,000.00 | $850,000.00 |
| 营业费用 | $24.11M | $22.40M | $74.62M | $22.16M | $17.90M |
| 销售及管理费用 | $6.05M | $6.74M | $21.97M | $5.58M | $4.87M |
| -管理费用 | $6.05M | $6.74M | $21.97M | $5.58M | $4.87M |
| 研发费用 | $18.07M | $15.66M | $52.65M | $16.58M | $13.03M |
| 营业利润 | -$23.94M | -$22.19M | -$74.08M | -$22.33M | -$17.05M |
| 非经营性利息净收入（支出） | $1.76M | $1.51M | $7.64M | $1.63M | $1.82M |
| 非经营性利息收入 | $1.76M | $1.51M | $7.64M | $1.63M | $1.82M |
| 其他收入（支出） | $672,000.00 | $854,000.00 | $1.52M | $905,000.00 | $616,000.00 |
| 特殊收益（费用） | -$300,000.00 | $0.00 | -$2.30M | -$400,000.00 | -$100,000.00 |
| -减：重组及并购费用 | $300,000.00 | $0.00 | $2.30M | $400,000.00 | $100,000.00 |
| 其他非经营性收入（支出） | $972,000.00 | $854,000.00 | $3.82M | $1.31M | $716,000.00 |
| 税前利润 | -$21.51M | -$19.82M | -$64.92M | -$19.80M | -$14.61M |
| 净利润 | -$21.51M | -$19.82M | -$64.92M | -$19.80M | -$14.61M |
| 持续经营利润 | -$21.51M | -$19.82M | -$64.92M | -$19.80M | -$14.61M |
| 归属母公司净利润 | -$21.51M | -$19.82M | -$64.92M | -$19.80M | -$14.61M |
| 归属普通股股东净利润 | -$21.51M | -$19.82M | -$64.92M | -$19.80M | -$14.61M |
| 基本每股收益 | -$0.15 | -$0.15 | -$0.53 | -$0.16 | -$0.12 |
| 摊薄每股收益 | -$0.15 | -$0.15 | -$0.53 | -$0.16 | -$0.12 |
资产负债表
| 项目 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| 总资产 | $179.69M | $198.72M | $160.46M | $160.46M | $175.53M |
| 流动资产合计 | $97.77M | $110.23M | $96.32M | $96.32M | $100.59M |
| 现金及现金等价物与短期投资 | $91.56M | $105.42M | $90.75M | $90.75M | $95.91M |
| -现金及现金等价物 | $19.17M | $28.66M | $19.96M | $19.96M | $25.26M |
| -短期投资 | $72.39M | $76.76M | $70.79M | $70.79M | $70.66M |
| 其他流动资产 | $6.21M | $4.81M | $5.57M | $5.57M | – |
| 非流动资产合计 | $81.93M | $88.49M | $64.14M | $64.14M | $74.94M |
| 固定资产净值 | $664,000.00 | $750,000.00 | $761,000.00 | $761,000.00 | $811,000.00 |
| 投资及预付款 | $79.07M | $85.37M | $60.61M | $60.61M | $71.30M |
| -可供出售证券 | $79.07M | $85.37M | $60.61M | $60.61M | $71.30M |
| 其他非流动资产 | $2.20M | $2.37M | $2.77M | $2.77M | $2.83M |
| 负债合计 | $55.11M | $55.07M | $57.38M | $57.38M | $55.43M |
| 流动负债合计 | $28.24M | $27.37M | $28.65M | $28.65M | $25.63M |
| 应付款 | $15.52M | $14.73M | $13.16M | $13.16M | $9.19M |
| -应付账款 | $15.52M | $14.73M | $13.16M | $13.16M | $9.19M |
| 一年内应计费用 | $3.08M | $3.85M | $3.49M | $3.49M | $3.66M |
| 一年内递延负债 | $3.98M | $3.97M | $3.94M | $3.94M | $6.30M |
| 其他流动负债 | $2.79M | $2.77M | $2.75M | $2.75M | $2.74M |
| 非流动负债合计 | $26.87M | $27.70M | $28.73M | $28.73M | $29.80M |
| 一年以上递延负债 | $14.31M | $15.29M | $16.17M | $16.17M | $17.49M |
| 其他非流动负债 | $12.56M | $12.42M | $12.57M | $12.57M | $12.31M |
| 股东权益合计 | $124.58M | $143.65M | $103.08M | $103.08M | $120.10M |
| 股东权益 | $124.58M | $143.65M | $103.08M | $103.08M | $120.10M |
| 股本 | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 |
| -普通股 | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 |
| -优先股 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 资本公积 | $1.13B | $1.13B | $1.07B | $1.07B | $1.07B |
| 留存收益 | -$1.01B | -$987.61M | -$967.78M | -$967.78M | -$947.99M |
| 不影响留存收益的损益 | -$304,000.00 | $22,000.00 | $610,000.00 | $610,000.00 | $597,000.00 |
| 应收款 | – | – | – | – | $4.68M |
| -应收账款 | – | – | – | – | $4.68M |
| -固定资产原值 | – | – | – | – | $5.80M |
| -累计折旧 | – | – | – | – | -$4.98M |
现金流量表
| 项目 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| 经营活动现金流 | -$19.85M | -$18.15M | -$47.11M | -$13.13M | -$10.93M |
| 持续经营经营活动现金流净额 | -$19.85M | -$18.15M | -$47.11M | -$13.13M | -$10.93M |
| 持续经营净利润 | -$21.51M | -$19.82M | -$64.92M | -$19.80M | -$14.61M |
| 折旧、折耗与摊销 | $107,000.00 | $102,000.00 | $454,000.00 | $102,000.00 | $110,000.00 |
| 营运资金变动 | -$1.42M | -$1.63M | $2.67M | $3.24M | $612,000.00 |
| -应付账款及应计费用变动 | $770,000.00 | -$1.51M | $350,000.00 | $5.21M | $1.67M |
| -其他营运资金变动 | -$972,000.00 | -$854,000.00 | -$3.82M | -$1.31M | -$715,000.00 |
| 投资活动现金流净额 | $10.26M | -$30.93M | $48.37M | $10.37M | $13.83M |
| 持续经营投资活动现金流净额 | $10.26M | -$30.93M | $48.37M | $10.37M | $13.83M |
| 固定资产购置及出售净额 | -$58,000.00 | -$13,000.00 | -$111,000.00 | -$24,000.00 | -$23,000.00 |
| 投资购置及出售净额 | $10.32M | -$30.92M | $49.31M | $10.39M | $13.85M |
| 筹资活动现金流 | $91,000.00 | $57.78M | -$5.86M | -$2.53M | -$3.04M |
| 持续经营筹资活动现金流净额 | $91,000.00 | $57.78M | -$5.86M | -$2.53M | -$3.04M |
| 普通股发行净额 | $0.00 | $57.88M | $0.00 | – | – |
| 股票期权行使所得 | $114,000.00 | $151,000.00 | $0.00 | $0.00 | $0.00 |
| 其他筹资费用净额 | -$23,000.00 | -$250,000.00 | -$5.86M | -$2.53M | -$3.04M |
| 期末现金余额 | $19.17M | $28.66M | $19.96M | $19.96M | $25.26M |
| 现金净变动 | -$9.49M | $8.70M | -$4.61M | -$5.30M | -$146,000.00 |
| 期初现金余额 | $28.66M | $19.96M | $24.57M | $25.26M | $25.40M |
| 自由现金流 | -$19.91M | -$18.16M | -$47.22M | -$13.16M | -$10.96M |
| -应收款变动 | – | $742,000.00 | – | – | – |
| 无形资产购置及出售净额 | – | $0.00 | $0.00 | – | – |
| 其他非现金项目 | – | – | $2.30M | $400,000.00 | $100,000.00 |
| -预付资产变动 | – | – | $6.14M | – | – |
| 业务购买及出售净额 | – | – | -$833,000.00 | $0.00 | $0.00 |
暂无评论——快来第一个聊聊 ACRS。
登录后参与讨论。